Press Statement In Response To Issues Raised By GAAS and General Public On The Proposed Vaccine Against Ebola Virus Phase II Clinical Trials In Ghana.

Background To A Phase l & ll Vaccine Studies Against Ebola Disease

The Ebola pandemic, which occurred across the world, with the epicenter in West Africa, led to over 25,000 cases and over 10,000 deaths. The absence of licensed drugs and vaccines contributed to the impact of the epidemic in the region. Even though the outbreak is vastly slowed, one missed infection could threaten weeks, even months of progress. There is therefore an urgent need for the development of vaccines to prevent infection and protect people from getting the disease.

The current proposed clinical trials in Ghana are to contribute towards the development of an effective vaccine to protect populations in future outbreaks for the disease in the region.

Rate this:

Read Article →